NOVAVAX ($NVAX) Releases Q3 2026 Earnings

NOVAVAX ($NVAX) reported Q3 2026 earnings of -$0.19 per share, beating estimates by $0.15. Revenue was $68.3M, exceeding expectations by $16.9M. Institutional investors showed mixed activity, with some increasing and others decreasing their positions.

Original reporting
Published Nov 5, 2026, 1:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
NOVAVAX ($NVAX) Releases Q3 2026 Earnings — source image
Decision brief

The 30-second read

$NVAXBullishMed
01

Why it matters

Earnings beat provides fresh data that could move the stock.

02

Market read

The earnings surprise offers a short‑term trading edge for NVAX.

03

What to watch

Potential upcoming regulatory or clinical trial milestones not discussed.

Relevance 6/10Novelty 7/10Timing: after market close

Background

Novavax is a vaccine developer; earnings releases are closely watched for pipeline progress.

Company-level read

Ticker impact

$NVAXBullishHigh confidence
Context

Novavax reported Q3 2026 earnings beating EPS and revenue estimates, providing fresh financial data.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The beat on both EPS (-$0.19 vs -$0.34) and revenue ($68.3M vs $51.4M) is material for a micro‑cap biotech and may trigger buying.

Market effects

Positive earnings may lift other small‑cap biotech stocks.

U.S. biotech sector could see modest gains.

Limited to investors tracking biotech earnings.

Counterpoint

The beat may be modest relative to cash burn; investors could stay cautious.

Key entities

  • Novavax

    Vaccine developer reporting Q3 2026 earnings.

Related articles

$NVAXHighAI 8/10

Novavax (NVAX) stock trades up, here is why

Novavax (NVAX) shares rose 8.8% after reporting Q3 2026 revenue of $68M and raising its full-year revenue outlook to $400M midpoint. The company also received a $125M milestone payment. NVAX reported a net loss of $31M, narrower than the prior year's $202M loss. The stock is up 49.4% YTD but remains 16.9% below its 52-week high.

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.